publication date: Dec. 13, 2019
Issue 46 - Dec. 13, 2019
  • “Call me Doctor”

    How women in oncology are fighting for cultural change

    A sense of foreboding descended on Narjust Duma as she sat at a presentation on drug-induced toxicities. The year was 2018, Duma was a 31-year-old second-year fellow at Mayo Clinic, and her discomfort stemmed from something other than the subject matter discussed.

  • Don’t call me Karen, Cheryl, Nancy, Reshma, Cornelia, Caryn, Sharon, … call me “Doctor.”

    Seven prominent women leaders in oncology—Karen Knudsen, Cheryl Willman, Reshma Jagsi, Nancy Davidson, Cornelia Ulrich, Caryn Lerman, and Sharon Stack—spoke with The Cancer Letter about their experiences with gender bias, implicit and explicit.

  • In Brief

    • Senate confirms Stephen Hahn as FDA commissioner
    • Moderate levels of alcohol consumption linked to higher risk of some cancers, NCI writes in JAMA
    • MSK to open David H. Koch Center for Cancer Care in January 2020
    • Thomas Jefferson University receives $70 million for new biomedical research building
    • Edmondo Robinson named chief digital innovation officer at Moffitt
    • Winship realigns its research programs to increase impact
  • TCCL Logo

  • Trials & Tribulations

    Nobel Prize Award: Impact of Clinical Care?

    On December 10, 2019, Dr. William G. Kaelin, Jr, Sir Peter J. Ratcliffe, and Dr. Gregg L. Semenza officially received the title of Nobel Laureate in Medicine.

  • Clinical Roundup

    • PD-1 inhibitor treatment prior to stem cell transplant is safe, effective in classic Hodgkin lymphoma
    • BMS’s liso-cel met primary, secondary endpoints in TRANSCEND NHL 001
    • Phase II KarMMa study of ide-cel in relapsed, refractory multiple myeloma meets ORR primary endpoint
    • Seattle Genetics announces positive OS, PFS, ORR for tucatinib in HER2+ breast cancer
    • ctDNA may help predict recurrence in patient with early triple-negative breast cancer
    • Extended follow-up phase III data underscore sustained efficacy and safety of Imbruvica in CLL
    • Phase III TOURMALINE-AL1 trial of Ninlaro in patients with amyloidosis didn’t meet one of two primary endpoints
    • Phase III SOPHIA study shows margetuximab didn’t reach significance for OS in HER2+ metastatic breast cancer
    • Keytruda improved OS in frontline metastatic NSCLC regardless of KRAS status
    • Venetoclax in reduced-intensity transplant conditioning regimen in high-risk myeloid cancers shows promise
  • Drugs & Targets

    • FDA issues draft guidance to foster pediatric oncology product development
    • FDA approves Avsola for same indications as Remicade
    • FDA grants Janssen’s BCMA CAR-T therapy JNJ-4528 Breakthrough Therapy Designation for multiple myeloma indication

Copyright (c) 2020 The Cancer Letter Inc.